NCT06643130

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 162 (estimated)
• Sponsor: JW Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia

Detailed description

To evaluate the efficacy and safety of co-administration of JW0104+C2402 in comparison with co-administration of JW0104+C2403 or C2402 alone in patients with hypertension and dyslipidemia.

Conditions

• Hypertension
• Dyslipidemia

Interventions

Type	Name	Description
DRUG	JW0104+C2402	For 8 weeks(PO (Per Oral), QD)
DRUG	JW0104+C2403	For 8 weeks(PO, QD)
DRUG	C2402	For 8 weeks(PO, QD)

Timeline

• Start date: 2024-12-02
• Primary completion: 2026-04-01
• Completion: 2026-04-01
• First posted: 2024-10-16
• Last updated: 2025-09-09

Locations

1 site across 1 country: South Korea